NewAmsterdam Pharma Company N.V. Earnings Per Share (Basic)
NewAmsterdam Pharma Company N.V. (NAMS) reported Earnings Per Share (Basic) of -$0.52 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-05
- NewAmsterdam Pharma Company N.V. earnings per share, basic for the quarter ending 2026-06-30 was -$0.52.
- NewAmsterdam Pharma Company N.V. earnings per share, basic for the quarter ending 2026-03-31 was -$0.40.
- NewAmsterdam Pharma Company N.V. earnings per share, basic for the quarter ending 2025-12-31 was -$0.62.
- NewAmsterdam Pharma Company N.V. earnings per share, basic for the quarter ending 2025-09-30 was -$0.61.
- NewAmsterdam Pharma Company N.V. earnings per share, basic for fiscal 2025 was -$1.72.
- NewAmsterdam Pharma Company N.V. earnings per share, basic for fiscal 2024 was -$2.56.
- NewAmsterdam Pharma Company N.V. earnings per share, basic for fiscal 2023 was -$2.15.
- NewAmsterdam Pharma Company N.V. earnings per share, basic for fiscal 2022 was -$1.19.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$0.52 10-Q · filed 2026-08-05 | -$0.92 10-Q · filed 2026-08-05 | -$1.53 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$2.14 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2026-03-31 | -$0.40 10-Q · filed 2026-05-07 | -$1.01 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$1.62 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$1.77 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-12-31 | -$0.62 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$1.22 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$1.37 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$1.72 10-K · filed 2026-02-18 |
| 2025-09-30 | -$0.61 10-Q · filed 2025-11-05 | -$0.75 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$1.09 10-Q · filed 2025-11-05 | -$1.96 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-06-30 | -$0.15 10-Q · filed 2026-08-05 | -$0.48 10-Q · filed 2026-08-05 | -$1.34 derived: net income ÷ weighted average shares · filed 2026-08-05 | -$1.55 derived: net income ÷ weighted average shares · filed 2026-08-05 |
| 2025-03-31 | -$0.34 10-Q · filed 2026-05-07 | -$1.23 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$1.44 derived: net income ÷ weighted average shares · filed 2026-05-07 | -$1.85 derived: net income ÷ weighted average shares · filed 2026-05-07 |
| 2024-12-31 | -$0.93 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$1.12 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$1.54 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$2.56 10-K · filed 2026-02-18 |
| 2024-09-30 | -$0.18 10-Q · filed 2025-11-05 | -$0.59 derived: net income ÷ weighted average shares · filed 2025-11-05 | -$1.61 10-Q · filed 2025-11-05 | -$2.21 derived: net income ÷ weighted average shares · filed 2026-05-06 |
| 2024-06-30 | -$0.41 10-Q · filed 2025-08-06 | -$1.45 10-Q · filed 2025-08-06 | -$2.06 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$2.64 derived: net income ÷ weighted average shares · filed 2026-05-06 |
| 2024-03-31 | -$1.06 10-Q · filed 2025-05-08 | -$1.68 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$2.26 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$2.73 derived: net income ÷ weighted average shares · filed 2026-05-06 |
| 2023-12-31 | -$0.60 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$1.17 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$1.64 derived: net income ÷ weighted average shares · filed 2026-05-06 | -$2.15 10-K · filed 2026-02-18 |
| 2023-09-30 | -$0.57 10-Q · filed 2024-11-06 | -$1.04 derived: net income ÷ weighted average shares · filed 2024-11-06 | -$1.55 10-Q · filed 2024-11-06 | |
| 2023-06-30 | -$0.47 10-Q · filed 2024-08-07 | -$0.98 10-Q · filed 2024-08-07 | ||
| 2023-03-31 | -$0.51 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | -$1.19 10-K · filed 2025-02-26 | |||
| 2021-12-31 | -$3.81 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |